Indian heart journal最新文献

A Cross-Sectional Study on the Incidence of Prosthetic Valve Thrombosis and its Outcome Treated with Fibrinolysis in a Tertiary Care Hospital.

IF 1.4

Indian heart journal Pub Date : 2025-02-07 DOI: 10.1016/j.ihj.2025.02.003

Dhiviya Murugesan, Balasubramanian Sundaram, Nagasundar Gurusamy, Hemanath Ramamurthy, Nisamudeen Kaja Mohideen

{"title":"A Cross-Sectional Study on the Incidence of Prosthetic Valve Thrombosis and its Outcome Treated with Fibrinolysis in a Tertiary Care Hospital.","authors":"Dhiviya Murugesan, Balasubramanian Sundaram, Nagasundar Gurusamy, Hemanath Ramamurthy, Nisamudeen Kaja Mohideen","doi":"10.1016/j.ihj.2025.02.003","DOIUrl":"https://doi.org/10.1016/j.ihj.2025.02.003","url":null,"abstract":"Aims: To find the incidence, risk factors of Prosthetic Valve Thrombosis (PVT). To study the efficacy, outcome and complications of fibrinolysis in PVT.Methods: Data from 44 consecutive patients admitted with PVT treated with fibrinolytics were assessed, outcomes recorded. Only medically managed PVT were included in this study and Surgical management were not included due to inadequate resources.Results: Out of 44 patients, 28 were female and 16 were male with mean age of 36.5 41 had underwent MVR, 3 had underwent DVR. 42 (92.4%) had thrombus at mitral valve 2 (4.5%) were at aortic valve. Visible clot was present in 7 (15.9%) and absent in 37 (84%) patients. 7 (15.9%) had recurrent episode of PVT. At the time of thrombolysis, no patient had major bleeding manifestation. During follow up after thrombolysis, 37 (84%) were alive and 7 (16%) expired. The incidence of primary end point i.e successful thrombolysis (as defined as complete response without complications ) was seen in 61.3% patients. The secondary end point i.e. Therapeutic failure/ death is recorded in 15.9% study subjects. Among the vulnerable population, therapeutic Failure/ death is seen with 57.1% sub-therapeutic anticoagulant consumers and 42.8% patients with poor drug compliance CONCLUSION: In conclusion this study sheds light on the complexities and challenges associated with prosthetic valve thrombosis in pregnant patients, patients with sub therapeutic anticoagulation or poor drug consumers. This study underscores the importance of close monitoring, optimal anticoagulation, patient education. This study highlights that fibrinolysis unless contraindicated can be considered as effective especially in developing countries or in centres with limited resources, where multiple factors such as surgical availability, financial cost, high operative mortality are to be weighed before treatment.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory cytokine levels in Rheumatic Heart Disease and their association with use of Benzathine Penicillin: A Case-Control Pilot Study.

IF 1.4

Indian heart journal Pub Date : 2025-02-06 DOI: 10.1016/j.ihj.2025.01.007

Sanjeev Kumar, Prakash Chand Negi, Sanjeev Asotra, Meenakshi Chandel, Jitender Kumar, Rajeev Merwah, Rajesh Sharma, Ritesh Kumar, Vinay Bhardwaj, Preetam Singh Thakur

{"title":"Inflammatory cytokine levels in Rheumatic Heart Disease and their association with use of Benzathine Penicillin: A Case-Control Pilot Study.","authors":"Sanjeev Kumar, Prakash Chand Negi, Sanjeev Asotra, Meenakshi Chandel, Jitender Kumar, Rajeev Merwah, Rajesh Sharma, Ritesh Kumar, Vinay Bhardwaj, Preetam Singh Thakur","doi":"10.1016/j.ihj.2025.01.007","DOIUrl":"https://doi.org/10.1016/j.ihj.2025.01.007","url":null,"abstract":"Background: Valvular inflammation plays an important role in the progression of Rheumatic Heart Disease. We report the association between inflammatory markers and use of Benzathine Penicillin G in patients with Rheumatic mitral valve disease.Methods: The levels of inflammatory cytokines; IL-1β, IL-6, TNF-α and inflammatory marker hs- CRP were measured using ELISA method in 32 patients with RHD receiving Benzathine Penicillin as secondary prophylaxis and 31 patients not receiving secondary prophylaxis, in a case-control study. The severity and type of valvular dysfunction were assessed with echocardiogram.Results: The median level of IL-1β was significantly lower in patients on BPG (0.95 pg/ml vs. 5.47 pg/ml) p<0.002. The median levels of IL-6, TNF-α and hs-CRP were not significantly different between study groups. The adjusted odds of raised IL-1β were lower in patients on BPG (odds ratio 0.40, 95% C.I. 0.11, 1.45) p 0.16. There was a trend of inverse association between the use of BPG and mitral stenosis (odds ratio 0.42, 95% C.I. (0.12, 1.46) p 0.17.Conclusion: Patients with RHD on BPG had lower levels of IL-1β and a trend toward a lower prevalence of mitral stenosis. Role of IL-1β in progression of incompetent to stenotic mitral valve dysfunction needs to be explored in future studies.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'Clopidogrel therapy in Acute Coronary Syndrome: Contemporary issues'.

IF 1.4

Indian heart journal Pub Date : 2025-02-05 DOI: 10.1016/j.ihj.2025.02.002

Satyavir Yadav, Rakesh Yadav

引用次数: 0

IVUS derived plaque characteristics and outcomes in patients with acute coronary syndrome undergoing percutaneous intervention.

IF 1.4

Indian heart journal Pub Date : 2025-02-04 DOI: 10.1016/j.ihj.2025.02.001

Sajan Narayanan, Vijayakumar Subban, Parayaru Kottayil Asokan, Ramesh Natarajan, K Latchumanadhas, V V Krishnakumar, Gopi Aniyathodiyil, Ravi Cheriyan Mathew, M Shifas Babu, ArjunS Shenoi, UdayKhanolkar, C G Bahuleyan

{"title":"IVUS derived plaque characteristics and outcomes in patients with acute coronary syndrome undergoing percutaneous intervention.","authors":"Sajan Narayanan, Vijayakumar Subban, Parayaru Kottayil Asokan, Ramesh Natarajan, K Latchumanadhas, V V Krishnakumar, Gopi Aniyathodiyil, Ravi Cheriyan Mathew, M Shifas Babu, ArjunS Shenoi, UdayKhanolkar, C G Bahuleyan","doi":"10.1016/j.ihj.2025.02.001","DOIUrl":"10.1016/j.ihj.2025.02.001","url":null,"abstract":"Background: No/slow flow after percutaneous intervention(PCI) for acute coronary syndromes (ACS) is common. Whether a comprehensive intravascular ultrasound (IVUS) analysis of atherosclerotic plaque can define characteristics which predict suboptimal flow following PCI is largely unknown.Objectives: To identify IVUS correlates of suboptimal flow in patients with ACS undergoing PCI.Materials & methods: We performed a prospective multicentre, investigator initiated study. Patients with ACS, who underwent IVUS guided PCI were enrolled. Clinical, angiographic and imaging characteristics of patients who developed suboptimal flow after PCI were analysed and compared with patients with normal flow.Results: Between October 2021 and August 2022, we enrolled 187 patients (195 lesions) with ACS who underwent IVUS guided PCI. Mean age of patients was 58 ± 10.4 years; Incidence of slow/no reflow in our study was 14/195 (7.2 %). Presentation as ST elevation myocardial infarction, presence of angiographically complex lesion type (type B2/C) and pre procedural TIMI flow 0 were significantly more in patients who developed suboptimal flow after PCI. Pre PCI plaque attenuation length (9.51 mm Vs 4.35 mm p = 0.037), lesion site positive remodelling (Odds ratio 6.4 : 95 % CI; 1.1-38.4 p = 0.042) were predictors of slow flow.Post PCI length of plaque prolapse (9.73 mm Vs 6.58 mm p = 0.029) correlated with slow flow.Conclusions: Plaque characteristics on IVUS in patients with ACS helps to identify patients who may develop suboptimal flow following PCI.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"A Study of Intracoronary Thrombolytic Agents In High Thrombus Burden Lesions During Primary PCI".

IF 1.4

Indian heart journal Pub Date : 2025-01-30 DOI: 10.1016/j.ihj.2025.01.008

Venkata Rs Subrahmanya Sarma, K Gopalakrishna, K Purnachandra Rao, G Somasekahr, P S S Chowdary, P Raghuram, B Dasarath, Manohar Reddy, Ramkishore, Raji Veeramachineni, Y Sasidhar, M Prasad

{"title":"\"A Study of Intracoronary Thrombolytic Agents In High Thrombus Burden Lesions During Primary PCI\".","authors":"Venkata Rs Subrahmanya Sarma, K Gopalakrishna, K Purnachandra Rao, G Somasekahr, P S S Chowdary, P Raghuram, B Dasarath, Manohar Reddy, Ramkishore, Raji Veeramachineni, Y Sasidhar, M Prasad","doi":"10.1016/j.ihj.2025.01.008","DOIUrl":"https://doi.org/10.1016/j.ihj.2025.01.008","url":null,"abstract":"Objectives: High thrombus burden during Primary Percutaneous Coronary Intervention begets poor outcomes; there are several lacunas in the management of those patients.- The purpose of this study is to analyse the long-term outcomes of patients undergoing primary percutaneous coronary intervention with high thrombus burden, treated with intracoronary thrombolysis as an adjunctive therapy.Methods: In this prospective observational study, 108 consecutive primary percutaneous coronary intervention patients with high thrombus burden were stratified into two groups basing on whether they received intracoronary thrombolytic agent before stent implantation. The primary outcome is Net Adverse Clinical Events. Secondary outcomes include Major Adverse Cardiac Events, and all other individual components of the Net Adverse Clinical Events when analysed separately.Results: The primary outcome events occurred in 21 patients (26%) in the Primary stent group (n=80), whereas it occurred in 2 patients (6%) in the primary intra-coronary thrombolysis group (n=28), this study shows that there is no difference in primary endpoints in both groups (26% Vs 7%, p-value - 0.042, Hazard ratio - 2.56; 95% CI - 0.76 - 8.57), however Kaplan-Meier event-free survival curves show that both the curves are well separated apart even at the end of the one year of follow - up.Conclusion: There is no difference in the primary outcome events in both groups, however there was a consistent increase in events in the primary stent group over the one-year follow-up period. These findings suggest the need for a larger randomized clinical trial to confirm and further elucidate these results.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Data presentation in industry-sponsored cardiac device trials.

IF 1.4

Indian heart journal Pub Date : 2025-01-24 DOI: 10.1016/j.ihj.2025.01.004

Baskaran Chandrasekar

引用次数: 0

Clonal hematopoiesis of indeterminate potential and cardiovascular diseases: A review.

IF 1.4

Indian heart journal Pub Date : 2025-01-23 DOI: 10.1016/j.ihj.2025.01.006

Nagendra Boopathy Senguttuvan, Vinodhini Subramanian, Muralidharan Tr, Kavitha Sankaranarayanan, Vettriselvi Venkatesan, Thanikachalam Sadagopan

{"title":"Clonal hematopoiesis of indeterminate potential and cardiovascular diseases: A review.","authors":"Nagendra Boopathy Senguttuvan, Vinodhini Subramanian, Muralidharan Tr, Kavitha Sankaranarayanan, Vettriselvi Venkatesan, Thanikachalam Sadagopan","doi":"10.1016/j.ihj.2025.01.006","DOIUrl":"10.1016/j.ihj.2025.01.006","url":null,"abstract":"Cardiovascular disease (CVD) is a major driver of mortality and declining health worldwide. Cardiovascular diseases (CVD) is the most common cause of morbidity and mortality globally. Although dyslipidemia, smoking, diabetes, hypertension and obesity are some well-known causes of CVD, the overlapping genetic pathways between other diseases and those affecting cardiovascular health have been overlooked. In the past decade, mutations in TET2, DNMT3A, ASXL1, and JAK2 are found to cause clonal hematopoiesis of intermediate potential (CHIP), a disease associated with age-related haematological malignancies without the presence of cytopenias or dysplasia. Coronary artery disease, heart failure, aortic stenosis, and arrhythmias have been shown to be associated with the presence of CHIP mutations. Addressing the association between CHIP could significantly reduce residual risk patients with CVD. The link between CHIP and CVD can potentially be addressed through inhibitors of inflammasomes, antagonists in the interleukin pathway, or direct antagonists of CHIP mutations.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of patient radiation exposure in coronary angiography via the trans-radial versus trans-femoral approach.

IF 1.4

Indian heart journal Pub Date : 2025-01-23 DOI: 10.1016/j.ihj.2025.01.005

Venkatesh Gurajala, Charishma Daruru, Kumar Narayanan, L Sridhar

{"title":"Comparison of patient radiation exposure in coronary angiography via the trans-radial versus trans-femoral approach.","authors":"Venkatesh Gurajala, Charishma Daruru, Kumar Narayanan, L Sridhar","doi":"10.1016/j.ihj.2025.01.005","DOIUrl":"10.1016/j.ihj.2025.01.005","url":null,"abstract":"Background: Cardiac catheterization via the trans-radial approach (TRA) has shown several advantages over the trans-femoral approach (TFA) but with a concern of higher radiation exposure. Considering the growing experience with TRA, this study compares patient's radiation during coronary angiography using TRA versus TFA.Methods: This study included consecutive patients undergoing coronary angiogram over a year at tertiary hospital performed by experienced operators through radial or femoral access. Parameters compared between the two routes included fluoroscopy time (FT), cineangiography time (CT), cini-sequences (CS), and patient radiation exposure quantified by Air Kerma (AK) and Dose Area Product (DAP).Results: A total of 910 patients were studied, with 461 (50.6 %) undergoing coronary angiography (CAG) via TFA and 449 (49.4 %) via TRA. The mean age was similar between the femoral (54.07) and radial groups (53.7) years (p = 0.33), with slightly lesser proportion of males in the femoral group (74.62 % vs 79.73 %; p = 0.06). The mean (SD) DAP and AK were 15.71 (7.05) Gy·cm2 and 258.3 (99.9) mGy for the femoral group, compared to 20.76 (9.48) Gy·cm2 and 352.2 (151.5) mGy for the radial group (both p < 0.001). The mean (SD) FT, CT, and CS were 1.32 (0.94) minutes, 40.4 (9) seconds, and 5.93 (1.22) for the femoral group, compared to 2.19 (1.67) minutes, 44 (10) seconds, and 6.17 (1.26) for the radial group (all p < 0.01).Conclusion: Coronary angiography via TRA is associated with increased patient's radiation. Future studies should investigate strategies to reduce radiation exposure in trans-radial procedures.","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of sarcoidosis in patients undergoing aortic valve replacement: Insight from nationwide readmission database 2016-2019. 结节病对主动脉瓣置换术患者的影响：来自2016-2019年全国再入院数据库的见解

IF 1.4

Indian heart journal Pub Date : 2025-01-16 DOI: 10.1016/j.ihj.2025.01.003

Kunal N Patel, Suryansh Bajaj, Monil Majmundar, Vidit Majmundar, Ankit Agrawal, Harshvardhan Zala, Rajkumar Doshi, Karandeep Singh, Avleen Kaur, Vyoma N Patel, Karthik Gonuguntla, Yasar Sattar, Ankur Kalra

引用次数: 0

Efficacy of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in right ventricular systolic dysfunction and preserved LV ejection fraction: A randomized clinical trial. 血管紧张素受体Neprilysin抑制剂（ARNI）对右心室收缩功能障碍和左室射血分数保存的疗效：一项随机临床试验。

IF 1.4

Indian heart journal Pub Date : 2025-01-12 DOI: 10.1016/j.ihj.2025.01.002

Rohit Mathur, Anil Baroopal, Chaina Ram Chaudhary, Afjal Hakim, Manoj Verma

引用次数: 0